Bank of New York Mellon Corp - EMERGENT BIOSOLUTIONS INC ownership

EMERGENT BIOSOLUTIONS INC's ticker is EBS and the CUSIP is 29089Q105. A total of 253 filers reported holding EMERGENT BIOSOLUTIONS INC in Q4 2021. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of EMERGENT BIOSOLUTIONS INC
ValueSharesWeighting
Q3 2023$813,817
-77.1%
239,358
-50.5%
0.00%
-100.0%
Q2 2023$3,554,291
-31.9%
483,577
-4.1%
0.00%0.0%
Q1 2023$5,221,845
-15.6%
504,039
-3.8%
0.00%0.0%
Q4 2022$6,184,660
-38.9%
523,680
+8.6%
0.00%
-50.0%
Q3 2022$10,120,000
-32.3%
482,164
+0.1%
0.00%
-33.3%
Q2 2022$14,953,000
-38.2%
481,774
-18.2%
0.00%
-40.0%
Q1 2022$24,197,000
-5.8%
589,279
-0.3%
0.01%0.0%
Q4 2021$25,685,000
-13.7%
590,887
-0.6%
0.01%
-16.7%
Q3 2021$29,751,000
-9.6%
594,188
+13.7%
0.01%0.0%
Q2 2021$32,911,000
-29.9%
522,457
+3.4%
0.01%
-40.0%
Q1 2021$46,946,000
+0.7%
505,294
-2.9%
0.01%0.0%
Q4 2020$46,610,000
-16.2%
520,216
-3.4%
0.01%
-28.6%
Q3 2020$55,637,000
+30.4%
538,430
-0.2%
0.01%
+27.3%
Q2 2020$42,679,000
+39.3%
539,688
+1.9%
0.01%
+10.0%
Q1 2020$30,640,000
+2.6%
529,542
-4.4%
0.01%
+25.0%
Q4 2019$29,870,000
-2.0%
553,691
-5.1%
0.01%0.0%
Q3 2019$30,487,000
+3.9%
583,149
-4.0%
0.01%0.0%
Q2 2019$29,349,000
-25.2%
607,502
-21.8%
0.01%
-27.3%
Q1 2019$39,253,000
-17.0%
776,991
-2.6%
0.01%
-26.7%
Q4 2018$47,279,000
-15.7%
797,594
-6.4%
0.02%
+7.1%
Q3 2018$56,077,000
+46.9%
851,840
+12.7%
0.01%
+40.0%
Q2 2018$38,167,000
-1.9%
755,948
+2.3%
0.01%
-9.1%
Q1 2018$38,915,000
+46.0%
739,147
+28.9%
0.01%
+57.1%
Q4 2017$26,648,000
+18.8%
573,450
+3.4%
0.01%
+16.7%
Q3 2017$22,422,000
+16.7%
554,345
-2.1%
0.01%
+20.0%
Q2 2017$19,210,000
+18.7%
566,478
+1.6%
0.01%
+25.0%
Q1 2017$16,184,000
-30.9%
557,297
-21.8%
0.00%
-42.9%
Q4 2016$23,413,000
+8.4%
712,928
+4.0%
0.01%
+16.7%
Q3 2016$21,604,000
+14.6%
685,194
+2.2%
0.01%0.0%
Q2 2016$18,849,000
-61.7%
670,318
-50.5%
0.01%
-60.0%
Q1 2016$49,182,000
-33.8%
1,353,022
-27.2%
0.02%
-31.8%
Q4 2015$74,328,000
+10.0%
1,857,734
-21.7%
0.02%
+4.8%
Q3 2015$67,580,000
-25.9%
2,372,022
-14.3%
0.02%
-16.0%
Q2 2015$91,227,000
+8.3%
2,768,652
-5.5%
0.02%
+13.6%
Q1 2015$84,237,000
+6.5%
2,928,950
+0.8%
0.02%
+4.8%
Q4 2014$79,112,000
+11.1%
2,905,332
-13.0%
0.02%
+10.5%
Q3 2014$71,180,000
-53.2%
3,340,263
-50.7%
0.02%
-5.0%
Q2 2014$152,072,000
+78.9%
6,770,792
+101.3%
0.02%
-13.0%
Q1 2014$84,982,000
+16.2%
3,362,908
+5.7%
0.02%
+15.0%
Q4 2013$73,136,000
-42.2%
3,181,248
-52.1%
0.02%
+5.3%
Q3 2013$126,500,000
+156.5%
6,640,394
+94.1%
0.02%
+18.8%
Q2 2013$49,322,0003,420,5020.02%
Other shareholders
EMERGENT BIOSOLUTIONS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Zebra Capital Management LLC 22,111$908,0002.08%
Global Alpha Capital Management Ltd. 460,530$18,909,0001.62%
AIMZ Investment Advisors, LLC 70,625$2,900,0001.19%
Bridge City Capital, LLC 39,835$1,636,0000.76%
PALISADE CAPITAL MANAGEMENT, LP 560,409$23,010,0000.53%
EARNEST PARTNERS LLC 2,071,376$85,051,0000.50%
RICE HALL JAMES & ASSOCIATES, LLC 302,721$12,430,0000.50%
SummerHaven Investment Management, LLC 14,476$594,0000.34%
Ridgewood Investments LLC 10,004$411,0000.27%
AtonRa Partners 11,505$472,0000.26%
View complete list of EMERGENT BIOSOLUTIONS INC shareholders